Oruka Therapeutics 

$48.53
42
-$1.9-3.77% Today

Statistics

Day High
51.01
Day Low
49.49
52W High
50.43
52W Low
6.78
Volume
1,006,783
Avg. Volume
537,822
Mkt Cap
2.35B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Aug 24
$19.36
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.46
-1.11
-0.75
-0.4
Expected EPS
-0.544427
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-225.39MNet Income

Analyst Ratings

$59.60Average Price Target
The highest estimate is 86.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ORKA. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech firm that develops cardiovascular drugs, competing directly with ARCA's heart failure treatments.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops a wide range of medications including those for cardiovascular diseases, directly competing with ARCA's portfolio.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that offers products in various therapeutic areas including cardiology, competing with ARCA's heart-related therapies.
Merck
MRK
Mkt Cap214.76B
Merck produces medications for various conditions, including heart diseases, making it a competitor in the cardiovascular space.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb develops a range of prescription medicines, including those for cardiovascular diseases, competing with ARCA.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs and other medications, including heart disease treatments, competing with ARCA.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, a research-based biopharmaceutical company, has a portfolio that includes cardiovascular drugs, competing with ARCA.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including cardiovascular, renal, and metabolism, making it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for cardiovascular diseases, competing with ARCA.
Sanofi
SNY
Mkt Cap124.45B
Sanofi focuses on healthcare solutions including cardiovascular diseases, directly competing with ARCA's therapeutic area.

About

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Show more...
CEO
Dr. Lawrence Otto Klein Ph.D.
Employees
28
Country
US
ISIN
US6876041087

Listings

0 Comments

Share your thoughts

FAQ

What is Oruka Therapeutics stock price today?
The current price of ORKA is $48.53 USD — it has decreased by -3.77% in the past 24 hours. Watch Oruka Therapeutics stock price performance more closely on the chart.
What is Oruka Therapeutics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Oruka Therapeutics stocks are traded under the ticker ORKA.
Is Oruka Therapeutics stock price growing?
ORKA stock has risen by +6.75% compared to the previous week, the month change is a +44.05% rise, over the last year Oruka Therapeutics has showed a +415.18% increase.
What is Oruka Therapeutics market cap?
Today Oruka Therapeutics has the market capitalization of 2.35B
When is the next Oruka Therapeutics earnings date?
Oruka Therapeutics is going to release the next earnings report on May 20, 2026.
What were Oruka Therapeutics earnings last quarter?
ORKA earnings for the last quarter are -0.45 USD per share, whereas the estimation was -0.64 USD resulting in a +29.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Oruka Therapeutics revenue for the last year?
Oruka Therapeutics revenue for the last year amounts to 0 USD.
What is Oruka Therapeutics net income for the last year?
ORKA net income for the last year is -225.39M USD.
Does Oruka Therapeutics pay dividends?
Yes, ORKA dividends are paid en. The last dividend per share was 19.36 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Oruka Therapeutics have?
As of April 02, 2026, the company has 28 employees.
In which sector is Oruka Therapeutics located?
Oruka Therapeutics operates in the Health Care sector.
When did Oruka Therapeutics complete a stock split?
The last stock split for Oruka Therapeutics was on September 03, 2024 with a ratio of 1:12.
Where is Oruka Therapeutics headquartered?
Oruka Therapeutics is headquartered in Menlo Park, US.